Vascular graft infections by Hasse, Barbara et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2013
Vascular graft infections
Hasse, Barbara; Husmann, Lars; Zinkernagel, Annelies; Weber, Rainer; Lachat, Mario; Mayer, Dieter
Abstract: Vascular procedures are rarely complicated by infection, but if prosthetic vascular graft in-
fection (PVGI) occurs, morbidity and mortality are high. Several patient-related, surgery-related and
postoperative risk factors are reported, but they are not well validated. PVGI is due to bacterial coloni-
sation of the wound and the underlying prosthetic graft, generally as a result of direct contamination
during the operative procedure, mainly from the patient’s skin or adjacent bowel. There is no consensus
on diagnostic criteria or on the best management of PVGI. On the basis of reported clinical studies and
our own experience, we advocate a surgical approach combining repeated radical local debridement, with
graft preservation whenever possible or partial excision of the infected graft, depending on its condi-
tion, plus simultaneous negative-pressure wound therapy (NPWT). In addition, antimicrobial therapy
is recommended, but there is no consensus on which classes of agent are adequate for the treatment of
PVGI and whether certain infections may be treated by means of NPWT alone. Since staphylococci and
Gram-negative rods are likely to be isolated, empirical treatment might include a penicillinase-resistant
beta-lactam or a glycopeptide, plus an aminoglycoside, the latter for Gram-negative coverage and syner-
gistic treatment of Gram-positive cocci. Additionally, empirical treatment might include rifampicin since
it penetrates well into biofilms.
DOI: 10.4414/smw.2013.13754
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: http://doi.org/10.5167/uzh-81653
Published Version
Originally published at:
Hasse, Barbara; Husmann, Lars; Zinkernagel, Annelies; Weber, Rainer; Lachat, Mario; Mayer, Dieter
(2013). Vascular graft infections. Swiss Medical Weekly, 143:w13754. DOI: 10.4414/smw.2013.13754
Review article: Current opinion | Published 24 January 2013, doi:10.4414/smw.2013.13754
Cite this as: Swiss Med Wkly. 2013;143:w13754
Vascular graft infections
Barbara Hassea, Lars Husmannb, Annelies Zinkernagela, Rainer Webera, Mario Lachatc, Dieter Mayerc
a Division of Infectious Diseases and Hospital Epidemiology, University Hospital and University of Zurich, Switzerland
b Clinic for Nuclear Medicine, University Hospital and University of Zurich, Switzerland
c Clinic for Cardiovascular Surgery, University Hospital and University of Zurich, Switzerland
Summary
Vascular procedures are rarely complicated by infection,
but if prosthetic vascular graft infection (PVGI) occurs,
morbidity and mortality are high. Several patient-related,
surgery-related and postoperative risk factors are reported,
but they are not well validated. PVGI is due to bacterial
colonisation of the wound and the underlying prosthetic
graft, generally as a result of direct contamination during
the operative procedure, mainly from the patient’s skin or
adjacent bowel. There is no consensus on diagnostic criter-
ia or on the best management of PVGI. On the basis of re-
ported clinical studies and our own experience, we advoc-
ate a surgical approach combining repeated radical local
debridement, with graft preservation whenever possible or
partial excision of the infected graft, depending on its con-
dition, plus simultaneous negative-pressure wound therapy
(NPWT). In addition, antimicrobial therapy is recommen-
ded, but there is no consensus on which classes of agent are
adequate for the treatment of PVGI and whether certain in-
fections may be treated by means of NPWT alone. Since
staphylococci and Gram-negative rods are likely to be isol-
ated, empirical treatment might include a penicillinase-res-
istant beta-lactam or a glycopeptide, plus an aminoglycos-
ide, the latter for Gram-negative coverage and synergistic
treatment of Gram-positive cocci. Additionally, empirical
treatment might include rifampicin since it penetrates well
into biofilms.
Key words: prosthetic vascular graft infection; negative
pressure wound therapy; graft preservation; 18F-
fluorodeoxyglucose positron emission
tomography;computed tomographic angiography
Introduction
Because of the growing prevalence of atherosclerosis and
diabetes, vascular grafts are increasingly used, and about
1–6% of vascular procedures are complicated by infection
[1]. Morbidity and mortality attributable to prosthetic vas-
cular graft infection (PVGI) are high [2, 3], and are highly
dependent on the location of the vascular graft, i.e., peri-
pheral or aortic. Peripheral graft infections occur in about
4% of cases and potentially lead to limb loss and increased
mortality; the rate of infection of aortic grafts is lower
(1–3%), but the attributable mortality is more than 20%
[3–5]. According to the Swiss Federal Office of Statistics,
9/100,000 persons are hospitalised because of PVGI, and
mean hospitalisation costs amount to 72,350 Swiss Francs
per patient.
Risk factors
Reported risk factors for the development of PVGI include
patient-related factors, such as older age, male sex, high
body mass index, heart failure, immunodeficiency, diabetes
mellitus, renal failure, chronic obstructive pulmonary dis-
ease, blood stream infection at the time of graft placement,
skin ulcers in the lower extremity and prolonged preoperat-
ive hospital stay [6–8]. Surgical risk factors include: arteri-
ography injection site within the operative area; groin in-
cision; prolonged, emergency, or “redo” vascular surgery;
bowel injury; extensive lymphatic manipulation; and tissue
injury during the dissection [4, 6, 7, 9]. Postoperative risk
factors include wound infections, and local complications
such as seroma or haematoma owing to pseudoaneurysm
or wound-bed bleeding [6, 8]. Other potential risk factors
pertain to the type of prosthetic graft. Although the incid-
ence of infection in polyester and polytetrafluoroethylene
(PTFE) grafts seems to be comparable, it has been hypo-
thesised that polyester grafts are more resistant than PTFE
grafts to eradication of infection [5].
Prevention
Direct inoculation of bacteria from the patient’s skin at the
time of surgery or direct spread of bacteria due to local tis-
sue breakdown may lead to surgical site infections. Most
PVGI occurs in the groin as a consequence of a progress-
ive surgical site infection. Factors that have been proved
to be associated with PVGI are: (1) prolonged preoperat-
ive hospital stay; (2) remote infection before elective vas-
cular surgery; (3) hair removal at the surgical incision site
with a razor; (4) simultaneous gastrointestinal procedures
during the insertion of an aortic graft; and (5) nasal car-
riage of Staphylococcus aureus (S. aureus). Several studies
have highlighted the importance of preoperative antibiotic
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prophylaxis, normothermia, control of blood glucose in the
setting of surgical procedures and patient surveillance for,
and eradication of, nasal S. aureus [3].
Pathogenesis
PVGI is due to bacterial colonisation of the wound and
the underlying prosthetic graft, generally because of direct
microbial contamination during the operative procedure by
the patient’s skin flora. Haematogenous spread of bacter-
ia may occur during dental manipulation, and urological
or endoscopic procedures. Other routes of infection are:
(1) contiguous spread from the adjacent or overlying tis-
sues; (2) bacterial colonisation of atherosclerotic plaques
surrounding the prosthetic vascular graft; or (3) colonisa-
tion of a thrombus in the aneurysmal sac of the vessel wall
[9]. Soft tissue oedema and injured skin structures may
add to the risk of PVGI [4]. The implantation of a vas-
cular prosthesis contributes to the risk of a vascular sur-
gical site infection through biofilm formation, which may
sustain bacterial colonisation, and protect microorganisms
from host defences and antimicrobial therapy. Staphylo-
cocci (S. aureus and coagulase-negative staphylococci) ac-
count for 80% of PVGIs [10], but fungi (mainly Candida),
other Gram-positive cocci (enterococci, streptococci), or
Gram-negative rods (mainly Eschericha coli, Pseudomo-
nas aeruginosa and Klebsiella spp.), are also reported to
cause PVGI [11]. Staphylococci and Pseudomonas spp.
are strong biofilm producers. PVGI is often polymicrobial,
with involvement of anaerobes, and there are cases where
cultures remain negative, often in the context of previous
antimicrobial therapy [10, 12].
Diagnostic procedures
The diagnosis of PVGI involves several elements, includ-
ing microbiological and clinical findings and imaging stud-
ies, as well as inflammatory markers.
Figure 1
FDG-PET: Distinct, focal metabolic activity (SUV 11.8) adjacent to
the Y- and renovisceral grafts (white arrow) with a spatial extension
to an abscess in the left psoas region (black arrow).
Microbiological diagnosis
Microorganisms retrieved from superficial or deep wounds
may simply represent colonising flora. Therefore, it is es-
sential to obtain bacterial cultures from the explanted
grafts, if available, or from tissue surrounding the graft
[12]. For adequate sampling, surgery is often mandatory.
Molecular methods such as the 16s rRNA polymerase
chain reaction (broad range PCR), and microbiological re-
covery techniques with broth cultures and sonication of the
graft, are used for diagnosis of PVGI [13, 14]. To date, the
relevance of cultures obtained from foams used for negat-
ive pressure wound therapy (NPWT) is still debated [15].
Clinical diagnosis
The clinical presentation of PVGI is very variable and de-
pends upon the location of the vascular graft (aortic or peri-
pheral) and upon the timing of the infection after surgery
(early or late).
Early infections develop less than 3 months after surgery.
They often present with acute onset of fever, bacteraemia,
pain, erythema, swelling, warmth, local bleeding, ulcer
formation, graft occlusion or a pulsatile mass (from mycot-
ic pseudoaneurysm) in the groin. Late infections develop
more than 3 months after surgery. They may present with
more subtle symptoms and signs such as back pain, fistula,
graft occlusion, asymptomatic pseudoaneurysm formation
and poor incorporation of the graft into the surrounding tis-
sue. Systemic manifestations of infection are often absent
(especially in diabetic patients) and blood cultures are of-
ten negative. Sometimes overlying soft tissue infections are
difficult to distinguish from PVGI. There are two classi-
fication systems for vascular graft infections (the Szilagyi
[16] and the Samson classifications [17]), which were de-
veloped for vascular groin infections in particular (table 1).
Imaging techniques
The methods most commonly used to evaluate whether
vascular grafts are infected include ultrasound, contrast en-
hanced computed tomographic angiography (CTA), 18F-
fluorodeoxyglucose positron-emission tomography (FDG-
PET) and fusion PET/computed tomography (CT). Peri-
graft fluid and inflammation can be rapidly identified with
ultrasound, but CT is generally considered the diagnostic
test of choice. CTA scans are assessed for the presence of
ectopic gas, perigraft fluid (<20 Hounsfield units), perigraft
soft tissue enhancement (>20 Hounsfield units), pseudoan-
eurysm formation, discontinuity of the aneurysmal sac and
an increased amount of soft tissue (>5 mm) between the
graft and the surrounding aneurysmal wall [18]. CT-guided
puncture may yield periprosthetic fluid for Gram stain and
culture to establish the microbiological diagnosis.
In advanced PVGI, the sensitivity of CTA is nearly 100%
[19]. However, in the case of low-grade PVGI, the risk
of false negative results is high [20]. Therefore, additional
imaging modalities are needed. The use of FDG-PET to
show the intensity (grade 0–4) and patterns (focal or dif-
fuse) of FDG uptake for the evaluation of infected vascular
grafts seems to be promising (figure 1). In a study of 33
consecutive patients with a suspected infected arterial pros-
thesis, FDG-PET showed a superior sensitivity (91% vs
64%), but a lower specificity (64% vs 84%) compared with
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CTA. However, when focal uptake was taken as the pos-
itive criterion in FDG-uptake [21, 22], the specificity and
positive predictive value of FDG-PET for the detection of
graft infection improved to 95% [23]. A recently developed
fusion technology of FDG-PET and CTA, in a single ses-
sion, enables the precise localisation of any abnormal FDG
uptake, and three studies have confirmed that PET/CTA is
a reliable tool for the diagnosis of PVGI [24–27]. However,
false-positive FDG uptake because of foreign body reac-
tion has to be taken into account [23].
Management
Up to now there are no clear guidelines for management
of PVGI, mainly because of the variable clinical present-
ation and the lack of data from randomised controlled tri-
als. Treatment modalities generally involve both surgical
intervention and systemic antibiotics. Antimicrobial ther-
apy alone without surgery is associated with a poor re-
sponse and high mortality, and is therefore not recommen-
ded [2]. However, small case series have shown promising
results for long-term suppressive antibiotic therapy in pa-
tients who are not fit for surgery because of co-morbidities
or an unacceptably high perioperative risk [28–30].
Surgical treatment
As well as aggressive debridement and the use of antibiot-
ics, many earlier treatment approaches recommended graft
excision and revascularisation through a non-infected field
in a one-stage procedure. The drawbacks of extra-anatom-
ic bypass revascularisation are long procedure time, low
patency, high amputation rates and the risk of rupture along
the suture line. These led to various graft-preserving treat-
ment options such as partial graft excision and in situ re-
construction with cryopreserved homografts, fresh arterial
allografts, autologous veins, or antibiotic- or silver-bonded
prosthetic grafts [3, 31–33] with or without muscle flap
coverage. The incidence of infection in arterial and vein
grafts is lower than in prosthetic vascular grafts, but com-
plications related to the harvest site should not be ignored
[8]. The antibiotics most commonly used to coat vascu-
lar grafts are fusidic acid, quinupristin-dalfopristin, van-
comycin, teicoplanin, gentamycin and rifampicin. Three
randomised controlled trials evaluated the efficacy of
rifampicin-bonded grafts in preventing early wound and/
or graft infection with promising results [34–36]. However,
genuine or acquired rifampicin resistance of microorgan-
isms isolated from PVGI has to be taken into account [33].
Although all these alternative techniques proved to be su-
perior to traditional methods in terms of rates of reinfec-
tion, conduit failure and amputation rates [37], overall mor-
tality was still high, underlining the need for novel surgical
approaches.
Negative pressure wound therapy (NPWT) has recently
provided new options for the treatment of infected vascular
wounds [38], although treating a vascular infection by
means of a local surgical therapy seems to be counterintuit-
ive. NPWT has been increasingly used for the treatment of
vascular surgical site infections either as a bridge to surgic-
al closure or as a primary wound treatment modality [11,
39–41]. Additionally, a combined endovascular and surgic-
al approach using radical debridement and NPWT on top
of an endograft has been reported to lower mortality in the
treatment of infected arterial ruptures [42].
Antimicrobial therapy
There is no consensus on which classes of antimicrobial
agents are adequate for empirical treatment of PVGI. The
British Society for Antimicrobial Chemotherapy (BSAC)
Steering Group on the treatment of hospital infections re-
commends combination treatment with cefuroxime and
metronidazole [43], but since staphylococciand Gram-neg-
ative rods are likely to be isolated, empirical treatment
might also include a penicillinase-resistant beta-lactam or
a glycopeptide, plus an aminoglycoside for Gram-negative
coverage and synergistic treatment in case of staphylo-
coccal infection [44]. In a French study involving 37 pa-
tients admitted to the Intensive Care Unit for suspected or
proven PVGI, combination therapy including aminoglyc-
osides was associated with a lower 30-day mortality [45].
Empirical antifungal therapy is probably not necessary, but
empirical combination treatment might include rifampicin
because of its good penetration into biofilms. When the
microorganisms involved are isolated, their susceptibility
should be tested in order to optimise bacterial coverage and
to narrow the antimicrobial spectrum.
For oral therapy, quinolones, trimethoprim-sulfameth-
oxazole, tetracyclines and rifampicin should preferably be
used because of their high oral bioavailability. An increas-
ing prevalence of multidrug-resistant organisms isolated
from PVGI has been observed in recent years [4, 46, 47].
Whether multidrug-resistant organisms must be considered
in the prophylaxis or empirical treatment of PVGI depends
on the local patterns of resistance in individual hospitals.
Details of the type and duration of antimicrobial therapy
are unfortunately often missing in reports of studies of
PVGI. A superficial infection might be treated with a
1-week course of oral antibiotics, whereas a deeper infec-
tion involving the subcutaneous tissue should presumably
be treated longer [39, 48, 49]. The duration of treatment
Table 1: Classification systems for vascular graft infections.
Szilagyi Classification
[16]
Samson Classfication
[17]
Group 1 Infection involves only the dermis Infection extends no deeper than the dermis
Group 2 Infection extends into the subcutaneous tissue but does not invade the
arterial implant
Infection involves subcutaneous tissues but does not come into grossly
observable direct contact with the graft
Group 3 The arterial implant proper is involved in the infection Infection involves the body of the graft but not at an anastomotic site
Group 4 Infection surrounds an exposted anastomosis, but bacteraemia or
anastomotic bleeding has not occurred
Group 5 Infection involves a graft-to-artery anastomosis and is associated with
septicaemia and/ or bleeding at the time of presentation
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for Szilagyi grade 3 or Samson grade 3–5 PVGI remains
uncertain, and is highly dependent on the extent of in-
fection, the location (peripheral or aortic), and the type
of graft material (synthetic, biological or vein). Presum-
ably, antimicrobial therapy should be prolonged, as is the
case with prosthetic valve endocarditis [50]. After surgic-
al debridement of the surrounding tissue (i.e., removal of
necrosis, infected tissues and biofilm) and the infected graft
(i.e., removal of biofilm), intravenous antimicrobial ther-
apy for at least 4–6 weeks is warranted. Calligaro et al. and
Legout et al. even suggest intravenous antibiotic treatment
for 6 weeks followed by oral antiinfective treatment for a
minimum of 6‒12 months [3, 44]. In a small case series
of nine Japanese patients with infected aortic grafts, sur-
viving individuals received intravenous antimicrobial treat-
ment followed by oral therapy for up to 3–6 months [51].
In a retrospective study of 68 infected autogenous vein
grafts, the duration of intravenous treatment was 3 weeks
without additional oral treatment [44]. However, in a recent
study, 20% of patients with Szilagyi grade 3 PVGI treated
with NPWT and graft preservation without administration
of any antibiotic showed good long-term results [11]. Fu-
ture studies should focus therefore not only on the various
forms of surgical treatment but especially on the need for
antibiotic treatment.
Outcome
Few studies have compared the outcomes of different sur-
gical strategies for treatment of vascular surgical site in-
fection. Ohta et al. compared different graft-removal tech-
niques with either extra-anatomic or in situ revascularisa-
tion, immediate vs staged timing of graft excision, and
different graft materials (prosthetic, autogenous or allo-
graft). The authors concluded that in situ techniques were
superior to extra-anatomic reconstructions in preventing
new graft failure and early mortality [51]. In another study
of 85 patients, age >70 years and aortic graft infection were
independent risk factors for in-patient mortality [44]. Graft
preserving techniques are increasingly used [3], and clin-
ical cure rates of up to 100% have been reported in small
case series if the graft was patent, and if there was no evid-
ence of systemic sepsis, local bleeding or formation of a
pseudoaneurysm [51]. For the largest series (44 patients),
Mayer et al. recently reported an excellent outcome with a
graft preserving approach including NPWT as an adjunct
[11]. All the patients survived 30 days. One-year mortal-
ity was 16% (7/44), and long-term mortality after a mean
follow-up of 43 months was 41% (18/44).
Conclusion
Prosthetic vascular graft infections are catastrophic events
with a high morbidity and mortality. To date, there is no
consensus about the best surgical treatment algorithm or
Table 2: Diagnosis and management of Prosthetic Vascular Graft Infection (PVGI).
Diagnostic or management modalities Remarks
Imaging
Extremities or neck Ultrasound Detection of pseudoaneurysms
Can be performed at the bedside
Thorax, abdomen or pelvis Combined FDG-PET/CTA Precise localisation of abnormal FDG uptake
Imaging-guided aspiration possible
MRI Good soft tissue resolution
Microbiology
Blood cultures Identification of microorganism and antimicrobial
resistance testing
Tissue cultures Identification of microorganism and antimicrobial
resistance testing
Broad range PCR Identification of microorganism if cultures are negative
>72 h
Surgery
Graft and anastomosis intact Graft preservation
Debridement
Negative pressure wound therapy
Plus antimicrobial therapy
Graft and anastomosis at risk for disruption Surgical removal of parts at risk
Local in situ reconstruction
Debridement
Negative pressure wound therapy
Plus antimicrobial therapy
Antimicrobial therapy
Empirical therapy Systemic manifestations, SIRS or surgical intervention
delayed (>24 h): Start empirical therapy immediately
No systemic manifestations, no SIRS and prompt surgical
intervention (<24 h): Hold antimicrobials until
microbiological results are available
Targeted therapy In accordance with blood cultures, surgical deep tissue
cultures or broad range PCR results
Suppressive therapy Long term suppressive antimicrobial therapy in the case of
inoperable situation
Abbreviations: FDG-PET, 18F-fluorodeoxyglucose positron-emission tomography; CTA, computed tomographic angiography; MRI, Magnetic resonance imaging; Broad
range PCR, 16s rRNA Gene Polymerase Chain Reaction; SIRS; Systemic inflammatory response syndrome
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antimicrobial management of PVGI. Recently, however,
more targeted and conservative approaches (graft pre-
serving techniques), especially when supported by NPWT,
have shown excellent long-term results in nonrandomised
case series. In order to address these uncertainties, we plan
to establish a prospective, observational cohort study of
a multidisciplinary approach to the management of PVGI
at the University Hospital of Zurich (VASGRA-Cohort).
Until further results are available, graft infection should be
treated according to current knowledge; this includes re-
peated radical local debridement, graft preservation (if pos-
sible), NPWT and targeted antimicrobial therapy (table 2).
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Figure 1
Distinct, focal metabolic activity (SUV 11.8) adjacent to the Y- and renovisceral grafts (white arrow) with a spatial extension to an abscess in the
left psoas region (black arrow). ■■ imaging technique?■■
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